SCHEMBL16745426

SCHEMBL16745426

O=C1C(O)=C(C2=C(Cl)C(=O)c3ccccc3C2=O)C(=O)c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 2/20 0.58
IDO1 P14902 1/20 0.58
DNMT1 P26358 1/20 0.58
DNMT3L Q9UJW3 1/20 0.58
DNMT3A Q9Y6K1 1/20 0.58
TDP2 O95551 1/20 0.58
MAPT P10636 7/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
NPSR1 Q6W5P4 3/20 0.46
GAA P10253 2/20 0.46
MAPK1 P28482 2/20 0.46
HTT P42858 2/20 0.46
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
MAPK10 P53779 1/20 0.44
HSD17B10 Q99714 1/20 0.44
P2RX7 Q99572 3/20 0.44
HSP90AA1 P07900 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29881216 0.87 IDO1 (0.75) APAF1IDO1DNMT1DNMT3LDNMT3A
SCHEMBL16745430 0.87 IDO1 (0.75) APAF1IDO1DNMT1DNMT3LDNMT3A
Bilawsone SCHEMBL3768549 0.87 APAF1 (0.75) APAF1IDO1DNMT1DNMT3LDNMT3A
Bilawsone SCHEMBL30884954 0.87 APAF1 (0.75) APAF1IDO1DNMT1DNMT3LDNMT3A
SCHEMBL16745450 0.86 S100A4 (0.61) APAF1IDO1DNMT1DNMT3LDNMT3A
SCHEMBL2126261 0.83 APAF1 (0.68) APAF1IDO1DNMT1DNMT3LDNMT3A
SCHEMBL22390154 0.81 EGFR (0.52) APAF1MAPTNPC1RAB9ANPSR1
SCHEMBL26655868 0.78 APAF1 (0.67) APAF1TDP2MAPTNPC1RAB9A
SCHEMBL7101602 0.77 FGFR1 (0.57) APAF1TDP2MAPTNPC1RAB9A
Sulfuric Acid SCHEMBL989869 0.76 APAF1 (0.58) APAF1IDO1DNMT1DNMT3LDNMT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 US disclosed
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 US disclosed
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-28 US disclosed
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148314-A1 SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS SDHA, KLK3, BRDT APAF1 955/4885IDO1 616/4885DNMT1 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.